Supp.B.
The RFs model outperformed the LDA model by a margin difference of up to 10% as seen in Table . 
Tuning of parameters for Random Forest models measuring accuracy and kappa values.
We performed a 10-fold cross validation evaluation of accuracy (percentage of correctly classified instances) and kappa (similar to the accuracy evaluation but normalized to account for any imbalances in the classes) metrics. We tried different values within these two parameters using the largest gene expression dataset (METABRIC). As shown in Figures B1 and B2 from Supp.B, mtry equal to 3 showed best average accuracy and kappa metrics. Nonetheless their values across one standard error show insignificant changes. We expected this to happen since 15 predictors is not a large enough count compared to other common gene expression studies. Therefore, we validated that the default value of mtry in the performed R randomForest model is appropriate, in our case mtry=3. In terms of ntree, it is commonly known that with the larger the number of trees, the performance metrics estimation improves but the computational time increases. For this reason, we ran all our RFs models with 10,000 trees. In the tuning experiment, we did not observe any statistical differences in the accuracy nor kappa values across 9000, 10000 and 11000 trees (See Supp. B: Figure B1 & Figure B2 ). Thus, the choice of parameters (mtry=3 and ntree=10000) suit our purposes when using METABRIC dataset. We expect similar results with all other datasets since the set of predictors we are evaluating is relatively small and the construction of 10,000 individual decision trees per forest model should provide good metrics' precision. 
Supp.C.
We only considered the following subtypes: Basal, Luminal A, Luminal B, HER2, Normal; as these are the most represented in literature and are used to classify breast cancer samples. A permutation test was performed to assess the predictive importance of the 15-gene signature in comparison with over one thousand random 15-gene sets. The Hh-mesenchyme signature ranked in the 85th percentile in terms of overall accuracy using the data from The Cancer Genome Atlas (TCGA).
Figure C1:
Histogram of accuracy values of 1000 random 15-gene sets compared to the Hh-mesenchyme signature towards breast cancer subtype discrimination using The Cancer Genome Atlas dataset.
Supp.D. Overall survival and Disease-Free Survival Analyses
The construction of hazard regression models is presented here. We incorporated several covariates including the 15-gene signature in both univariate and multivariate models using all samples from the METABRIC dataset (See Table D1 and Table D3 ). The hazard models for Basal samples (Table D2) did not produce significant expression patterns to discriminate survival. However, in Luminal A samples, further subgrouping of these samples, based on expression levels of genes such as IGFBP6, could improve clinical outcome and better therapeutic options assessments (see Table 2 and Table D4 ). 
Overall Survival by Receptor Status
Figure D1 Study of overall and disease-free survival across Luminal A and basal samples from the METABRIC dataset across different therapeutic approaches. Heatmap is sorted by disease-free survival.
Supp.E.
The gene signature did a better job characterizing resistant versus sensitive cases than subtypes. GLI1, GLI2
and SMO were found as the most relevant genes to discriminate these cases using MDG score from the RFs.
All three genes tend to be less expressed in most of the sensitive instances and highly expressed in the resistant ones as shown in the heatmaps here.
Figure E1:
Heatmaps of resistant and sensitive samples across the Hedgehog-mesenchyme 15-gene expression for GSE58375 and GSE77042.
